Physician profile
Shakeel Tabish
NPI 1114451523
$582.24
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $92.62 · 2021: $149 · 2022: $124 · 2023: $216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $216.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $130.48 | 2021 | |
| Novartis Pharmaceuticals Corporation | $101.32 | 2023 | |
| Mdd US Operations, LLC | $53.45 | 2022 | |
| Acadia Pharmaceuticals INC | $45.73 | 2023 | Nuplazid |
| Biohaven Pharmaceutical Holding Company LTD. | $40.60 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $32.32 | 2023 | Austedo |
| Tanabe Pharma America, INC. | $22.00 | 2019 | |
| Amneal Pharmaceuticals LLC | $20.26 | 2019 | |
| Akcea Therapeutics, INC. | $19.53 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $18.90 | 2021 | |
| Upsher-Smith Laboratories LLC | $18.47 | 2023 | |
| Argenx US, INC. | $18.33 | 2023 | Vyvgart |
| Acorda Therapeutics, INC | $18.31 | 2019 | |
| Janssen Pharmaceuticals, INC | $17.37 | 2022 | |
| Lilly USA, LLC | $12.65 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $12.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shakeel Tabish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.